Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia

Background A combination of horse anti-thymocyte globulin and cyclosporine produces responses in 60–70% of patients with severe aplastic anemia. We performed a phase II study of rabbit anti-thymocyte globulin and cyclosporine as first-line therapy for severe aplastic anemia. Design and Methods Twenty patients with severe aplastic anemia treated with rabbit anti-thymocyte globulin were compared to 67 historical control cases with matched clinical characteristics treated with horse anti-thymocyte globulin. Results Response rates at 3, 6 and 12 months were similar for patients treated with rabbit anti-thymocyte globulin or horse anti-thymocyte globulin: 40% versus 55% (P=0.43), 45% versus 58% (P=0.44) and 50% versus 58% (P=0.61), respectively. No differences in early mortality rates or overall survival were observed. We then performed multivariable analyses of response at 6 months and overall survival and identified the presence of a paroxysmal nocturnal hemoglobinuria clone (P=0.01) and a pretreatment absolute reticulocyte count greater than 30×109/L (P=0.007) as independent predictors of response and younger age (P=0.003), higher pretreatment absolute neutrophil (P=0.02) and absolute lymphocyte counts (P=0.03) as independent predictors of overall survival. None of the immunogenetic polymorphisms studied was predictive of response to immunosupressive therapy. Conclusions Despite reports suggesting differences in biological activity of different anti-thymocyte globulin preparations, rabbit and horse anti-thymocyte globulin appear to have a similar efficacy for up-front treatment of severe aplastic anemia. Clinicaltrial.gov: NCT01231841)

[1]  N. Young,et al.  Current concepts in the pathophysiology and treatment of aplastic anemia. , 2013, Hematology. American Society of Hematology. Education Program.

[2]  H. Kantarjian,et al.  Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. , 2010, Blood.

[3]  Z. Estrov,et al.  Updated Results of Combination Cytokine Immunotherapy In the Treatment of Aplastic Anemia and Myelodysplastic Syndrome (MDS) , 2010 .

[4]  N. Young,et al.  A Randomized Trial of Horse Versus Rabbit Antithymocyte Globulin In Severe Acquired Aplastic Anemia , 2010 .

[5]  E. H. Atta,et al.  Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study , 2010, Annals of Hematology.

[6]  Kihyun Kim,et al.  Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia , 2010, European journal of haematology.

[7]  E. Colado,et al.  Comparison Between Lymphoglobuline- and Thymoglobuline-Based Immunosuppressive Therapy as First-Line Treatment for Patients with Aplastic Anemia. , 2009 .

[8]  M. Wlodarski,et al.  Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia , 2009, Haematologica.

[9]  E. Gluckman,et al.  Cord blood transplantation: state of the art , 2009, Haematologica.

[10]  H. Kantarjian,et al.  Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome , 2009, Leukemia.

[11]  N. Young,et al.  Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia , 2009, British journal of haematology.

[12]  P. Munson,et al.  Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. , 2007, Blood.

[13]  S. Fischer,et al.  Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. , 2006, Blood.

[14]  J. Passweg,et al.  Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). , 2007, Haematologica.

[15]  L. Gondek,et al.  Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. , 2006, Blood.

[16]  Yizhou Zheng,et al.  Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. , 2006, Experimental hematology.

[17]  N. Young,et al.  Retreatment with rabbit anti‐thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia , 2006, British journal of haematology.

[18]  Xingmin Feng,et al.  Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. , 2006, Blood.

[19]  A. Zanella,et al.  Immunoregulatory cytokine polymorphisms in Italian patients affected by paroxysmal nocturnal haemoglobinuria and aplastic anaemia. , 2004, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[20]  S. Sakaguchi,et al.  CD4+ Tregs and immune control. , 2004, The Journal of clinical investigation.

[21]  H. Heimpel,et al.  A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes , 2004, Leukemia.

[22]  M. Maschan.  Horse ATG (ATGAM) versus rebbit ATG (Fresenius) for treatment of aplastic anemia in children : result of prospective double-blind randomized single-centre trial , 2004 .

[23]  N. Young,et al.  Is there a direct effect of antithymocyte globulin on hematopoiesis? , 2004, The hematology journal : the official journal of the European Haematology Association.

[24]  M. Murphy,et al.  Direct binding of antithymoctye globulin to haemopoietic progenitor cells in aplastic anaemia , 2003, British journal of haematology.

[25]  D. Follmann,et al.  Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. , 2003, JAMA.

[26]  H. Heimpel,et al.  Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. , 2003, Blood.

[27]  G. Mufti,et al.  A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low‐risk’ myelodysplasia , 2003, British journal of haematology.

[28]  E. Estey,et al.  Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes , 2003, Leukemia.

[29]  H. Schrezenmeier,et al.  Clinical relevance of the TNF-alpha promoter/enhancer polymorphism in patients with aplastic anemia , 2002, Annals of Hematology.

[30]  N. Young,et al.  HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. , 2002, Blood.

[31]  D. Follmann,et al.  Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. , 2001, Blood.

[32]  N. Young,et al.  Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol‐anchored protein‐deficient clones , 2001, British journal of haematology.

[33]  E. Gordon-Smith,et al.  Mechanisms of bone marrow progenitor cell apoptosis in aplastic anaemia and the effect of anti‐thymocyte globulin: examination of the role of the Fas–Fas‐L interaction , 2000, British journal of haematology.

[34]  H. Heimpel,et al.  Emergence of CD 52-, Phosphatidylinositolglycan-Anchor-Deficient T Lymphocytes After In Vivo Application of Campath-1 H for Refractory B-Cell Non-Hodgkin Lymphoma , 2000 .

[35]  F. Rodeghiero,et al.  Rabbit antithymocyte globulin (r‐ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy , 1999, British journal of haematology.

[36]  N. Young,et al.  Antithymocyte globulin for patients with myelodysplastic syndrome , 1997, British journal of haematology.

[37]  N. Young,et al.  The pathophysiology of acquired aplastic anemia. , 1997, The New England journal of medicine.

[38]  H. Heimpel,et al.  Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. , 1995, Blood.

[39]  P. Meusers,et al.  Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. , 1991, The New England journal of medicine.